• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Zenas BioPharma Inc.

    3/11/25 6:51:25 AM ET
    $ZBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZBIO alert in real time by email
    S-8 1 tm258608d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on March 11, 2025 

    Registration No. 333-

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION 

    WASHINGTON, DC 20549

     

     

     

    FORM S-8 

    REGISTRATION STATEMENT 

    UNDER 

    THE SECURITIES ACT OF 1933

     

     

     

    ZENAS BIOPHARMA, INC. 

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   93-2749244

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

       

    852 Winter Street, Suite 250

    Waltham, MA

      02451
    (Address of Principal Executive Offices)   (Zip Code)

     

    Zenas BioPharma, Inc. 2024 Equity Incentive Plan 

    Zenas BioPharma, Inc. 2024 Employee Stock Purchase Plan 

    (Full titles of the plans)

     

     

     

    Leon O. Moulder, Jr. 

    Chief Executive Officer 

    Zenas BioPharma, Inc.

    852 Winter Street, Suite 250 

    Waltham, MA 02451 

    (Name and address of agent for service)

     

    (857) 271-2954 

    (Telephone number, including area code, of agent for service)

     

     

     

    Please send a copy of all communications to:

     

    Thomas Danielski 

    Nicholas Roper 

    Ropes & Gray LLP 

    Prudential Tower 

    800 Boylston Street 

    Boston, MA 02199-3600 

    617-951-7000

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ¨   Accelerated filer   ¨
    Non-accelerated filer   x   Smaller reporting company   x
            Emerging growth company   x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ¨

     

     

     

     

     

     

    EXPLANATORY NOTE 

    REGISTRATION OF ADDITIONAL SHARES

     

    Zenas BioPharma, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 with the Securities and Exchange Commission (the “Commission”) for the purpose of registering (i) 2,089,670 additional shares of its common stock, par value $0.0001 per share (“Common Stock”), under the Zenas BioPharma, Inc. 2024 Equity Incentive Plan (the “2024 Plan”), pursuant to the provisions of the 2024 Plan providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the 2024 Plan on January 1, 2025, and (ii) 417,934 additional shares of Common Stock under the Zenas BioPharma, Inc. 2024 Employee Stock Purchase Plan (as amended and restated, the “ESPP”), pursuant to the provisions of the ESPP providing for an automatic increase in the number of shares of Common Stock reserved and available for issuance under the ESPP on January 1, 2025. Pursuant to General Instruction E to Form S-8, the Registrant incorporates by reference, except to the extent supplemented, amended or superseded by the information set forth herein, into this Registration Statement the entire contents of its Registration Statement on Form S-8 (File No. 333- 282151) filed with the Commission on September 16, 2024.

     

    PART II 

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

    Exhibit    
       
    4.1   Restated Certificate of Incorporation (previously filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on September 16, 2024 and incorporated herein by reference).
       
    4.2   Amended and Restated Bylaws (previously filed as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on September 16, 2024 and incorporated herein by reference).
         
    4.3   Zenas BioPharma, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 4.6 to the registration statement on Form S-8 filed on September 16, 2024, File No. 333-282151).
       
    4.4   Zenas BioPharma, Inc. 2024 Employee Stock Purchase Plan, as amended and restated (incorporated by reference to Exhibit 10.18 to the Registrant’s Annual Report on Form 10-K, filed on March 11, 2025).
       
    5.1*   Opinion of Ropes & Gray LLP
       
    23.1*   Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm
       
    23.2*   Consent of Ropes & Gray LLP (included in the opinion filed as Exhibit 5.1)
       
    24.1*   Powers of Attorney (included on the signature page in Part II)
         
    107*   Filing Fee Table.

     

     

    * Filed herewith.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Massachusetts, on this 11th day of March, 2025.

     

      ZENAS BIOPHARMA, INC.
         
      By: /s/ Leon O. Moulder, Jr.
        Name: Leon O. Moulder, Jr.
        Title:   Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints Leon O. Moulder, Jr. and Joseph Farmer, and each of them singly, his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 to be filed by Zenas BioPharma, Inc. and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and each of them, or their substitutes, may lawfully do or cause to be done by virtue hereof.

     

    * * * *

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

     

    Signature   Title   Date
             

    /s/ Leon O. Moulder, Jr.

    Leon O. Moulder, Jr.

     

    Chief Executive Officer and Director

    (Principal Executive Officer)

      March 11, 2025
             

    /s/ Jennifer Fox

    Jennifer Fox

     

    Chief Business Officer, Chief Financial Officer and Treasurer

    (Principal Accounting and Financial Officer)

      March 11, 2025
             

    /s/ Patricia Allen

    Patricia Allen

      Director   March 11, 2025
             

    /s/ James Boylan

    James Boylan

      Director   March 11, 2025
             

    /s/ Patrick Enright

    Patrick Enright

      Director   March 11, 2025
             

    /s/ Tomas Kiselak

    Tomas Kiselak

      Director   March 11, 2025
             

    /s/ Hongbo Lu, Ph.D.

    Hongbo Lu, Ph.D.

      Director   March 11, 2025
             

    /s/ Jake Nunn

    Jake Nunn

      Director  

    March 11, 2025

             

    /s/ John Orloff, M.D.

      Director   March 11, 2025
    John Orloff, M.D.        
             

    /s/ Ting Xiao

    Ting Xiao

      Director   March 11, 2025

     

     

     

    Get the next $ZBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZBIO

    DatePrice TargetRatingAnalyst
    3/20/2025$35.00Outperform
    Wedbush
    2/4/2025$19.00Outperform
    Wolfe Research
    12/16/2024$30.00Buy
    H.C. Wainwright
    11/5/2024$34.00Buy
    Rodman & Renshaw
    10/8/2024$45.00Buy
    Guggenheim
    10/8/2024$40.00Overweight
    Morgan Stanley
    10/8/2024$35.00Buy
    Jefferies
    10/8/2024$27.00Buy
    Citigroup
    More analyst ratings

    $ZBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Xiao Ting bought $77,600 worth of shares (10,000 units at $7.76) (SEC Form 4)

      4/A - Zenas BioPharma, Inc. (0001953926) (Issuer)

      4/28/25 7:07:52 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Moulder Leon O Jr bought $166,750 worth of shares (25,000 units at $6.67), increasing direct ownership by 10% to 266,155 units (SEC Form 4)

      4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

      2/19/25 4:01:11 PM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Xiao Ting bought $77,600 worth of shares (10,000 units at $7.76), increasing direct ownership by 27% to 47,000 units (SEC Form 4)

      4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

      2/11/25 4:20:30 PM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wedbush initiated coverage on Zenas Biopharma with a new price target

      Wedbush initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $35.00

      3/20/25 8:00:59 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Zenas Biopharma with a new price target

      Wolfe Research initiated coverage of Zenas Biopharma with a rating of Outperform and set a new price target of $19.00

      2/4/25 7:13:29 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Zenas Biopharma with a new price target

      H.C. Wainwright initiated coverage of Zenas Biopharma with a rating of Buy and set a new price target of $30.00

      12/16/24 6:47:20 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ZBIO
    SEC Filings

    See more
    • Zenas BioPharma to Present at the Jefferies Global Healthcare Conference

      WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced management's presentation at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 1:25 p.m. ET. A live webcast and archived replay of the Company's presentation can be accessed under "Events and Presentations" in the Investor & Media Relations section of the Zenas BioPharma website. About Zenas BioPharma, Inc.Zenas is a clinical-stage global biopharmaceutical company committed to becomin

      5/29/25 7:05:00 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates

      - Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Phase 2 MoonStone trial in Relapsing Multiple Sclerosis enrollment concluding; topline results expected early in the fourth quarter 2025 - - Enrollment of Phase 2 SunStone trial in Systemic Lupus Erythematosus expected to be completed by year-end 2025; topline results expected mid-2026 - - Strengthened leadership team with appointments of Lisa von Moltke, M.D., Head of Research and Development and Chief Medical Officer, and Haley Laken, Ph.D., Chief Scientific Officer - - Cash, cash equivalents and investments of $314.2 million as of March 31, 2025, expected to provi

      5/15/25 7:05:00 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on April 15, 2025 (the "Grant Date"), the Compensation Committee of the Company's Board of Directors (the "Committee") granted non-qualified stock options to two newly hired officers of the Company, each as an inducement material to each officer's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4). The Committee granted a non-qualified stock option to purchase

      4/17/25 4:20:32 PM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Zenas BioPharma Inc.

      10-Q - Zenas BioPharma, Inc. (0001953926) (Filer)

      5/15/25 7:25:28 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zenas BioPharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Zenas BioPharma, Inc. (0001953926) (Filer)

      5/15/25 7:14:53 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Zenas BioPharma Inc.

      SCHEDULE 13G/A - Zenas BioPharma, Inc. (0001953926) (Subject)

      5/12/25 10:20:43 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Xiao Ting bought $77,600 worth of shares (10,000 units at $7.76) (SEC Form 4)

      4/A - Zenas BioPharma, Inc. (0001953926) (Issuer)

      4/28/25 7:07:52 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Von Moltke Lisa

      4 - Zenas BioPharma, Inc. (0001953926) (Issuer)

      4/17/25 4:01:17 PM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Von Moltke Lisa

      3 - Zenas BioPharma, Inc. (0001953926) (Issuer)

      3/21/25 4:01:08 PM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Zenas BioPharma Inc.

      SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

      11/12/24 10:40:28 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Zenas BioPharma Inc.

      SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

      10/21/24 4:18:16 PM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Zenas BioPharma Inc.

      SC 13G - Zenas BioPharma, Inc. (0001953926) (Subject)

      9/25/24 6:00:11 PM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer

      WALTHAM, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Haley Laken, Ph.D., as Chief Scientific Officer (CSO). Dr. Laken brings significant scientific insight and leadership experience in research, development operations, R&D strategy and business development. "Haley is an accomplished R&D leader with expertise in translational research, drug development and operations. She has advanced programs through the clinic leading to regulatory approv

      4/7/25 7:05:00 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

      –Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ:ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced the appointment of Lisa von Moltke, M.D., as its Head of Research and Development and Chief Medical Officer (CMO). Dr. von Moltke brings over 30 years of U.S. and international drug development experience s

      3/17/25 7:05:00 AM ET
      $ZBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care